Drug Safety Final Guidances To Be Published In March, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will publish three final guidances related to prescription drug safety in March, FDA Office of New Drugs Deputy Director Sandra Kweder said
You may also be interested in...
FDA To Name IoM Safety Review Committee Members April 18
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
FDA To Name IoM Safety Review Committee Members April 18
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.